{"nctId":"NCT02925494","briefTitle":"An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","startDateStruct":{"date":"2016-09-14","type":"ACTUAL"},"conditions":["Uterine Fibroids","Heavy Menstrual Bleeding"],"count":433,"armGroups":[{"label":"Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA)","type":"EXPERIMENTAL","interventionNames":["Drug: Estradiol/Norethindrone Acetate","Drug: Elagolix"]},{"label":"Elagolix","type":"EXPERIMENTAL","interventionNames":["Drug: Elagolix"]}],"interventions":[{"name":"Estradiol/Norethindrone Acetate","otherNames":[]},{"name":"Elagolix","otherNames":["ABT-620","elagolix sodium"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant has completed the 6-Month Treatment Period of their respective Pivotal Study (either Study M12-815 or Study M12-817).\n* Participant did not meet removal criteria in bone mineral density (BMD) decrease in the spine, total hip and femoral neck at Month 6 of the Treatment Period of their respective Pivotal Study\n* Participant has negative urine and/or serum pregnancy test(s) results were consistently negative during the Treatment Period of their respective Pivotal Study and prior to first dose in this study.\n* Participant's endometrial biopsy from the Month 6 Visit of their respective Pivotal Study shows no clinically significant endometrial pathology.\n\nExclusion Criteria:\n\n* Participant met criteria for removal from therapy in her respective Pivotal Study.\n* Participant is planning a pregnancy within the next 18 months.\n* Participant has current suicidal markers as noted at the Month 6 visit of her respective pivotal study.\n* Participant has any new medical conditions that may be unsuitable for participation.\n* Participant is using any systemic corticosteroids for over 14 days or is likely to require treatment with systemic corticosteroids during the course of the study. Over-the-counter and prescription topical, inhaled, intranasal or injectable (for occasional use) corticosteroids are allowed.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"51 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Meeting the Criteria for Responder","description":"Percentage of responders, defined as participants who met the following conditions:\n\n* Menstrual blood loss (MBL) volume \\< 80 mL during the Final Month (the last 28 days prior to and including the last dose date), and\n* ≥ 50% reduction in MBL volume from Baseline to the Final Month.\n\nParticipants who prematurely discontinued study drug due to \"lack of efficacy,\" \"requires surgery or invasive intervention for treatment of uterine fibroids,\" or \"adverse events\" were considered non-responders regardless of whether she meets the two aforementioned responder criteria or not.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"89.4","spread":null},{"groupId":"OG003","value":"87.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in MBL Volume For Each 28-Day Interval and Final Month of the Treatment Period","description":"Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period of the pivotal study, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-151.7","spread":"184.76"},{"groupId":"OG001","value":"-61.7","spread":"212.01"},{"groupId":"OG002","value":"-253.4","spread":"190.07"},{"groupId":"OG003","value":"-186.5","spread":"164.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-210.9","spread":"234.01"},{"groupId":"OG001","value":"-203.1","spread":"188.15"},{"groupId":"OG002","value":"-249.7","spread":"189.81"},{"groupId":"OG003","value":"-191.9","spread":"166.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-236.9","spread":"162.33"},{"groupId":"OG001","value":"-209.0","spread":"184.90"},{"groupId":"OG002","value":"-255.9","spread":"175.43"},{"groupId":"OG003","value":"-200.6","spread":"159.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-235.1","spread":"184.87"},{"groupId":"OG001","value":"-204.5","spread":"177.65"},{"groupId":"OG002","value":"-252.0","spread":"175.23"},{"groupId":"OG003","value":"-200.5","spread":"156.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-237.3","spread":"234.00"},{"groupId":"OG001","value":"-194.5","spread":"213.69"},{"groupId":"OG002","value":"-253.9","spread":"173.50"},{"groupId":"OG003","value":"-192.9","spread":"165.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-263.8","spread":"199.83"},{"groupId":"OG001","value":"-175.4","spread":"115.43"},{"groupId":"OG002","value":"-279.1","spread":"191.44"},{"groupId":"OG003","value":"-211.4","spread":"165.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-256.6","spread":"194.04"},{"groupId":"OG001","value":"-186.4","spread":"138.16"},{"groupId":"OG002","value":"-250.3","spread":"182.09"},{"groupId":"OG003","value":"-205.6","spread":"151.55"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in MBL Volume For Each 28-Day Interval and Final Month of the Treatment Period","description":"Baseline MBL volume was defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period of the pivotal study, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) was greater than 80 mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.5","spread":"66.57"},{"groupId":"OG001","value":"-28.2","spread":"72.69"},{"groupId":"OG002","value":"-94.0","spread":"24.90"},{"groupId":"OG003","value":"-87.7","spread":"36.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.2","spread":"46.33"},{"groupId":"OG001","value":"-79.4","spread":"41.80"},{"groupId":"OG002","value":"-93.3","spread":"28.77"},{"groupId":"OG003","value":"-87.8","spread":"43.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-89.9","spread":"37.62"},{"groupId":"OG001","value":"-82.9","spread":"34.79"},{"groupId":"OG002","value":"-96.9","spread":"16.88"},{"groupId":"OG003","value":"-90.6","spread":"32.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-90.3","spread":"30.26"},{"groupId":"OG001","value":"-82.7","spread":"32.76"},{"groupId":"OG002","value":"-95.2","spread":"19.38"},{"groupId":"OG003","value":"-91.2","spread":"28.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-90.0","spread":"40.38"},{"groupId":"OG001","value":"-75.0","spread":"65.97"},{"groupId":"OG002","value":"-97.7","spread":"13.01"},{"groupId":"OG003","value":"-87.5","spread":"40.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-91.8","spread":"30.77"},{"groupId":"OG001","value":"-79.3","spread":"32.25"},{"groupId":"OG002","value":"-99.2","spread":"4.31"},{"groupId":"OG003","value":"-89.7","spread":"36.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-91.0","spread":"28.74"},{"groupId":"OG001","value":"-78.5","spread":"36.76"},{"groupId":"OG002","value":"-96.6","spread":"18.29"},{"groupId":"OG003","value":"-90.8","spread":"33.01"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Suppression of Bleeding at the Final Month","description":"Suppression of bleeding is defined as having 0 days of bleeding (spotting is allowed) during the Final Month with the interval starting from Study Day 11.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.7","spread":null},{"groupId":"OG001","value":"56.0","spread":null},{"groupId":"OG002","value":"89.2","spread":null},{"groupId":"OG003","value":"74.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Baseline Hemoglobin Concentration ≤ 10.5 g/dL and an Increase From Baseline > 2 g/dL at Month 6 During the Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"36.4","spread":null},{"groupId":"OG002","value":"71.4","spread":null},{"groupId":"OG003","value":"72.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":59},"commonTop":["HOT FLUSH","NIGHT SWEATS","HEADACHE","NAUSEA","NASOPHARYNGITIS"]}}}